/ /

  • linkedin
  • Increase Font
  • Sharebar

    FOURIER Clinical Outcomes Trial Results: Center Stage at ACC.17

    FOURIER was a double blind randomized placebo-controlled trial with 27,564 patients conducted at 1242 sites in 49 countries.

    • Patients were diagnosed with atherosclerotic cardiovascular disease (ASCVD), baseline LDL ≥70 mg/dL, and already receiving statins.
    • Patients were randomized to placebo or evolocumab (420 mg/month or 140 mg every other week)
    • Two year outcomes presented at the American College of Cardiology (ACC) 2017 Scientific Sessions, March 2017, in Washington, DC.
    • Primary Endpoint: composite of CV death, MI, stroke, hospitalization for unstable angina, coronary revascularization
    • Secondary Endpoint: composite of CV death, MI, stroke

    Find study details in the slides that follow.